Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Selexis S.A.. (3/30/16). "Press Release: Selexis SA Announces Spring 2016 Conference Schedule". Geneva.

Organisations Organisation Selexis S.A.
  Group JSR Corporation (Group)
  Organisation 2 University of Lausanne (UNIL)
Products Product cell line development (recombinant protein production)
  Product 2 SUREtechnology Platform™ (Selexis)
Person Person Fisch, Igor (Selexis 201008 CEO + co-founder)

Selexis leadership planning for active line up of speaking engagements, partnering and exhibit activities, and sponsorships

Selexis SA, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, announced today its planned participation at several conferences this Spring, as follows:

BIO-Europe Spring® 2016
4 - 6 April 2016, Berzelii Park, Stockholm, Sweden

Selexis Chief Executive Officer and Chairman Igor Fisch, PhD, will participate in a panel discussion entitled “The Alliance Manager: Bridging the Culture Gap,” on 4 April at 2:45 p.m. CET. Selexis will also be participating in the partnering program.

For more information visit:

Cell Line Development & Engineering: Practical Strategies to Improve Cell Line Quality, Enhance Productivity and Increase Throughput without Compromising Timelines
11 - 13 April 2016, Reed Messe Wien Congress Center, Vienna, Austria

Selexis Scientific Founder, Board Member and Scientific Advisor Nicolas Mermod, PhD, University of Lausanne, will present on 12 April at 4:05 p.m. CET during the Selection Strategies session on “Implementing Next Generation Sequencing in Routine Cell Line Development.” Selexis is also a sponsor and exhibitor.

For more information visit:

12th Annual PEGS Boston: The Essential Protein Engineering Summit
25 - 29 April 2016, Seaport World Trade Center, Boston, Massachusetts, USA

Selexis Chief Scientific Officer Pierre-Alain Girod, PhD, will present on 27 April at 12:25 p.m. EST during the Optimizing Antibody Selection and Screening session on “Analysis of the Genomics and Transcriptomics of CHO-K1 to Accelerate and De-risk Biologics Development.” Selexis is also a sponsor and exhibitor.

For more information visit:

2016 BIO International Convention
6 - 9 June 2016, Moscone Center, San Francisco, California, USA

Selexis will be participating in the partnering program and is also an exhibitor.

For more Information visit:

About Selexis SA

Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’s SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With nearly 90 clients worldwide and more than 65 drug products in clinical and commercial manufacturing utilizing its cell lines, Selexis has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research.


- Web
- LinkedIn
- Twitter
- Facebook

Record changed: 2017-07-02


Picture EBD Group Bio-Europe 2018 Copenhagen Denmark November 600x60px

More documents for JSR Corporation (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px

» top